Skip to main content

CASI Granted Breakthrough Status in China for CD19 CAR-T Therapy

CASI Pharma, a US-China biopharma, announced its partnered CD19 CAR-T product was granted Breakthrough Designation in China for relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). In 2019, CASI acquired global rights to co-develop the candidate with Juventas Cell Therapy, a Tianjing City company, by making an $11.6 million investment in Juventas. Juventas remains responsible for clinical work in China . It started a China Phase II trial of CNCT19 in patients with B-ALL recently. More details.... Stock Symbol: (NSDQ: CASI) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.